Category: Press Releases

Les deux sociétés vont collaborer à l’élaboration de logiciels destinés aux sociétés biotechnologiques et pharmaceutiques afin de créer plus rapidement des traitements améliorés pour les patients

SALT LAKE CITY, TORONTO et MONTRÉAL, 13 juill. 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), société biotechnologique au stade clinique chef de file dans le décodage biologique pour l’industrialisation de la découverte de médicaments, a annoncé aujourd’hui un investissement de 50 millions de dollars de NVIDIA, effectué sous forme de Placement privé dans les sociétés ouvertes (PPSO) Recursion a également annoncé son intention, en collaboration avec NVIDIA, d’accélérer le développement de ses modèles biologiques et chimiques basés sur l’IA afin de les optimiser et de les distribuer aux sociétés biotechnologiques en utilisant les services infonuagiques de NVIDIA.

« Notre collaboration avec NVIDIA représente l’union de deux sociétés de premier plan pour contribuer à résoudre l’un des plus grands défis au monde, la découverte de médicaments », a déclaré Chris Gibson, cofondateur et chef de la direction de Recursion. « Grâce à notre puissant ensemble de données et aux capacités informatiques accélérées de NVIDIA, nous avons l’intention de créer des modèles biologiques et chimiques de base, et ce, à une échelle sans précédent relativement à ce qui a été fait dans le domaine biologique ».

Recursion prévoit d’utiliser son vaste et exclusif ensemble de données biologiques et chimiques, dépassant 23 pétaoctets et 3 000 milliards de gènes et de relations des gènes et des composés consultables, afin d’accélérer la formation de modèles de base sur le nuage NVIDIA DGX en vue d’une éventuelle licence commerciale/diffusion sur BioNeMo, le service infonuagique de NVIDIA pour l’IA générative dans le domaine de la découverte de médicaments. NVIDIA aidera également à optimiser et à faire évoluer les modèles de base Recursion en s’appuyant sur la pile IA et l’expertise informatique complète de NVIDIA. BioNeMo a été annoncé au début de l’année comme un service infonuagique pour l’IA générative destinée à la découverte de médicaments, offrant des outils pour personnaliser et déployer rapidement des modèles biomoléculaires de pointe à l’échelle, spécifiques à un domaine, par le biais de services API en nuage. Recursion prévoit d’utiliser ce logiciel pour soutenir sa réserve de projets interne ainsi que ses partenaires actuels et futurs.

« L’IA générative est un outil innovant pour découvrir de nouveaux médicaments et traitements », a déclaré Jensen Huang, fondateur et chef de la direction de NVIDIA. « Nous sommes ravis de collaborer avec l’équipe de classe mondiale de Recursion, qui effectue un travail innovant en biologie et chimie numériques avec NVIDIA DGX et le logiciel NVIDIA AI afin d’accélérer le développement des plus grands modèles d’IA générative biomoléculaire au monde et la découverte de médicaments pour les sociétés biotechnologiques et pharmaceutiques »

Recursion, par  l’acquisition récente de Valence Discovery, vise à accélérer le développement de nouvelles technologies pour alimenter l’industrie biopharmaceutique, tout en démocratisant l’accès aux modèles à grande échelle qui ont un impact maximal sur la découverte de médicaments.

À propos de Recursion 
Recursion (NASDAQ: RXRX) est une société biotechnologique en stade clinique, chef de file dans son domaine, qui décode les données biologiques pour industrialiser la recherche de nouveaux médicaments. Pour s’acquitter de sa mission, Recursion OS, plateforme mise au point à partir de technologies variées, étend continuellement l’un des plus grands ensembles de données chimiques et biologiques au monde. Recursion s’appuie sur des algorithmes d’apprentissage automatique sophistiqués pour extraire de son ensemble de données une collection de billions de relations consultables dans les domaines de la biologie et de la chimie, qui ne sont pas limitées par les biais humains. Par la possession et l’exploitation de l’un des plus puissants des superordinateurs au monde, et des recherches expérimentales menées une échelle expérimentale massive – jusqu’à des millions d’expériences en laboratoire humide hebdomadaires – et une échelle de calcul massive, Recursion unit la technologie, la biologie et la chimie pour faire progresser l’avenir de la médecine.

Recursion est basée à Salt Lake City, où elle est membre fondateur de BioHive, le collectif de l’industrie des sciences de la vie de l’Utah. Recursion possède également des bureaux à Toronto, Montréal et dans la région de San Francisco Bay. Pour en savoir plus, consultez le site www.Recursion.com, ou connectez-vous sur Twitter et LinkedIn.

Personne-ressource pour les médias
Media@Recursion.com

Contact auprès des investisseurs
Investor@Recursion.com

Énoncés prospectifs
Ce document contient des informations qui incluent ou sont basées sur des « Énoncés prospectifs » au sens du Securities Litigation Reform Act de 1995, y compris, mais sans s’y limiter, celles concernant l’accélération et l’avancement du développement des modèles de fondation de l’IA, ainsi que l’optimisation, l’octroi de licences et la distribution de ces modèles; l’utilisation du logiciel BioNeMo pour soutenir le pipeline interne de Recursion ainsi que les partenaires industriels actuels et futurs de Recursion ; Recursion accélérant le développement de nouvelles technologies grâce à l’acquisition de Valence Discovery; ainsi que toutes les autres déclarations qui ne constituent pas des faits historiques. Les énoncés prospectifs peuvent inclure ou non des mots d’identification tels que « prévoit », « fera », « s’attend à », « anticipe », « a l’intention de », « croit », « potentiel », « continue » et des termes similaires. Ces énoncés sont soumis à des risques connus ou inconnus et à des incertitudes qui pourraient faire en sorte que les résultats réels diffèrent matériellement de ceux exprimés ou sous-entendus dans ces énoncés, y compris, mais sans s’y limiter : les défis inhérents à la recherche et au développement pharmaceutiques, y compris le calendrier et les résultats des programmes précliniques et cliniques, où le risque d’échec est élevé et où l’échec peut survenir à n’importe quel stade avant ou après l’approbation réglementaire en raison d’un manque d’efficacité suffisante, de considérations de sécurité ou d’autres facteurs; notre capacité à exploiter et à améliorer notre plate-forme de découverte de médicaments; notre capacité à obtenir un financement pour les activités de développement et d’autres objectifs de l’entreprise; le succès de nos activités de collaboration; notre capacité à obtenir l’approbation réglementaire des médicaments candidats et à les commercialiser; notre capacité à obtenir, maintenir et appliquer les protections de la propriété intellectuelle; les cyberattaques ou autres perturbations de nos systèmes technologiques; notre capacité à attirer, motiver et retenir des employés clés et à gérer notre croissance; l’inflation et d’autres questions macroéconomiques; et d’autres risques et incertitudes tels que ceux décrits sous la rubrique « Facteurs de risque » dans les documents que nous avons déposés auprès de la U. S. Securities and Exchange Commission. Securities and Exchange Commission, y compris notre rapport annuel sur le formulaire 10-K. Toutes les déclarations prospectives sont basées sur les estimations, projections et hypothèses actuelles de la direction, et Recursion ne s’engage pas à corriger ou mettre à jour ces déclarations, que ce soit à la suite de nouvelles informations, de développements futurs ou autres, sauf dans la mesure où la loi applicable l’exige.

GlobeNewswire Distribution ID 8873841

PETAH TIKVA, Israel and TYSONS CORNER, Va., July 12, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced it will report its second-quarter 2023 financial results before market open on Tuesday, August 8, 2023.

Later that same morning, Cellebrite will host a live conference call and webcast to review the Company’s financial results for the first quarter of 2023 and discuss its full-year 2023 outlook. Pertinent details include:

Date:	Tuesday, August 8, 2023
Time:	8:30 a.m. ET
Call-In Number:	203-518-9848
Conference ID:	CLBTQ223
Event URL:	https://investors.cellebrite.com/events/event-details/cellebrite-q2-23-earnings
Live Webcast URL:	https://edge.media-server.com/mmc/p/f896bks4

In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results. A transcript of the call will be added to this page along with access to the replay of the call.

About Cellebrite
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com.

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Caution Regarding Forward Looking Statements

This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 29, 2022,as amended on April 14, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

GlobeNewswire Distribution ID 8873303

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.

“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.”

Recursion plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX Cloud for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. NVIDIA will also help optimize and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. BioNeMo was announced earlier this year as a cloud service for generative AI in drug discovery, offering tools to quickly customize and deploy domain-specific, state-of-the-art biomolecular models at-scale through cloud APIs. Recursion anticipates using this software to support its internal pipeline as well as its current and future partners.

“Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”

Recursion, through its recent acquisition of Valence Discovery, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratizing access to large-scale models that have maximum impact in drug discovery.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the acceleration and advancement of development of AI foundation models, as well as optimizing, licensing, and distributing such models; using BioNeMo software to support Recursion’s internal pipeline and well as Recursion’s current and future industry partners; Recursion accelerating development of new technologies through its Valence Discovery acquisition; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 8872969

Roseau, July 12, 2023 (GLOBE NEWSWIRE) — As the European Union, the United Kingdom, and the United States tighten their grips on immigration policies, Kenyan investors are feeling the pinch of hyperinflation and global markets affecting their abilities to trade and travel to these countries.

Kenyan investors are making the most of the citizenship by investment (CBI) programmes in the Caribbean, more particularly in the Commonwealth of Dominica. Dominica CBI programme offers better lifestyle opportunities from quality education to healthcare system; the country has some of the best medical facilities in the world, with financial support from the CBI programme. the country’s official language is English, closely followed by Dominican Creole, which is French based, amongst local citizens.

The ‘Nature Island of the Caribbean’ is also economically and politically stable, and it is one of the fastest-growing economies in the Caribbean region. The IMF predicted that the country would exceed growth of over 4.5 per cent for 2023, including the full recovery of the tourism sector post-pandemic, as the construction of the geothermal power plant and the new international airport are projected to support Dominica’s gross domestic product (GDP), as well as the expansion of Douglas Charles Airport runway.

In May this year, Dominica Prime Minister, Honourable Dr. Roosevelt Skerrit, alongside Dominica Education Minister, Octavia Alfred, and Parliamentary Secretary, Fenella Wenham-Sheppard, had met with principles from secondary schools to discuss the education reform in the country. The discussion included possibilities to review the national education system. These discussions are to effect change towards a stronger education system to ensure all students in Dominica can access fundamental education and develop their learning experiences.

Dominica has quality healthcare facilities that align with international standards. Earlier this year, Honourable Dr. Skerrit announced changes to the country’s healthcare policy that Dominican citizens should all have access to quality medical facilities, despite their economic status and the Dominican youth between 16 to 18 years of age will have access to free medical care in the country. The Minister of Health, Wellness and Social Services of Dominica, Cassani Laville, guided a tour around the Marigot hospital and the state-of-the-art medical treatment facilities that will be available to the public from July 2023. The Marigot Hospital is another representation of the government of Dominica’s goals in becoming the world’s first climate-resilient nation.

The island is also an ideal retirement location for senior Kenyan citizens, with additional healthcare benefits. Dominica’s CBI Programme has sustained a flourishing expat community by providing opportunities in a favourable business environment, and for their families to reside in a safe and secure lifestyle.

Dominica CBI Programme

Dominica CBI Programme is one of the youngest and most affordable CBI programmes in the Caribbean region and one of the most recognised globally. A “Plan B” for Kenyans to secure their personal well-being, families and the future of their businesses, in a world filled with uncertainties. There are two distinct investment options that have favourable offerings for Kenyan investors to acquaint themselves with.

Economic Diversification Fund (EDF)

For as little as US$100,000 (estimated KSh14,000.000), the EDF is an investment option centered around socio-economic development. This is an element in the national capital mobilisation portfolio. Funds accumulated through EDF support the construction of schools, the development of medical facilities, agriculture and tourism sectors, as well construction of a national sports stadium.

Dominica is actively striving to become the world’s first climate-resilient country and fulfil sustainable development goals. Various government projects such as the planning of the geothermal power plant have gained traction in the latest developments. A Joint Venture between Dominica Geothermal Development Company and a Trinidad and Tobago company, Kenesjay Green, are driving the advancements of the geothermal and hydrogen projects in Dominica. Evolving the country’s energy into renewable energy will make Dominica one of the global exporters of green hydrogen energy, as well as propel economic development in key sectors such as tourism.

Launched in 2018, the Climate Resilience Execution Agency for Dominica (CREAD) was formed to strategically support the economic development of the country. There are 20 targets, which are separated into 6 categories that are strong communities; Robust Economy; Durable Infrastructure; Enhanced Institutional Systems; Collective Consciousness; and Protected and Sustainability Leveraged Natural and Other unique Assets. that are highlighted that Dominica aims to achieve by the year 2030.

These are noteworthy government initiatives that are tackling climate change critical to Dominica for preparedness and preservation of the natural environment around the Nature Isle of the Caribbean.

Real Estate

Kenyan investors can splurge on the Real Estate investment option that has a variety of government-approved properties that offer unique luxurious experiences for affluent Kenyans that seek decadent lifestyle choices. The minimum contribution amount is US$200,000 (estimated KSh36,000,000) towards an approved real estate property.

This investment option has the flexibility of permitting Kenyans to hold the real estate property for a period of three years from the date of citizenship approval, or for five years should the potential future buyer be a CBI applicant.

There are government fees attached to each application should the main Kenyan applicant want to include dependants, which consists of a spouse (next of kin):

• US$25,000 (estimated KSh3,500,000) for the main applicant;
• US35,000 (estimated KSh4,900,000) for the main applicant and up to three dependants;
• US$50,000 (estimated KSh7,000,000) for the main applicant and up to five dependants;
• US$25,000 (estimated KSh3,500,000) for additional dependants.

There are due diligence and processing fees applied per application.

Dominica has some of the global award-winning unique real estate properties that are on-demand and have potentially high Return on Investment (ROI) earnings for discerning Kenyan investors.

Dominica’s first government-approved real estate is the InternContinental Dominica Carbits Resort & Spa, the luxurious property is located on the beachfront of Douglas Bay that boasts sustainable elements which furnish memorable experiences that Kenyans will have like never before.

The Residences at Secret Bay are deemed the crown jewel of the Nature Isle of the Caribbean. The eco-luxury villas received recognition from Travel + Leisure, Luxury Lifestyle Magazine, Forbes and many more reputable global publications. From breathtaking views, activities for thrill seekers and luxurious dining experiences, the Secret Bay is nothing less than spectacular.

Sanctuary Rainforest Eco Resort and Spa will be located in Roseau Valley, which will offer a truly serene eco-luxury resort that morphs with nature. The resort is currently being constructed in the Morne Trois Pitons National Park and will be nestled close to Middleham Falls. The resort will have high-end luxury spa facilities and fine-dining restaurants.

Chantal Mabanga
Commonwealth of Dominica
+44 (0) 207 318 4343
chantal.mabanga@csglobalpartners.com

GlobeNewswire Distribution ID 8873103

QUEBEC CITY, July 12, 2023 (GLOBE NEWSWIRE) — LeddarTech^®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, is thrilled to announce the successful integration of LeddarTech’s advanced LeddarVision software with Ficosa’s cutting-edge surround-view camera system, along with other sensors such as radars, IMU and GPS. Ficosa is a leading global company dedicated to the research, development, production and marketing of advanced vision, safety and efficiency solutions for the automotive industry.

This significant milestone marks a major step forward in the strategic collaboration announced in December 2022 by Ficosa regarding integrating the LeddarVision software into Ficosa’s advanced driver assistance systems (ADAS) for parking. LeddarVision is a high-performance sensor fusion and perception software stack that provides extremely accurate 3D models of the vehicle’s surroundings, developed using raw data inputs from sensor systems. Integrating this software with Ficosa’s renowned vision technology unlocks the full potential of this software to enable Ficosa’s smart parking assistant for ADAS and AD.

In pursuit of their shared vision towards the consolidation of the autonomous vehicle, LeddarTech and Ficosa continue to strengthen their strategic collaboration towards developing a pioneering Intelligent Parking Assistance system, allowing even more detailed and precise perception of the surroundings. The hardware and software system architecture teams will begin equipping a car in Israel that will be used, in collaboration, to develop and demonstrate the smart parking assistance perception and driving features. Following this, two other vehicles in Europe will be added to the fleet showcasing the full software and hardware implementation for smart parking assist.

“LeddarTech is very pleased to partner in this collaboration and celebrate the success of integrating our LeddarVision software and Ficosa vision technology.” So stated Charles Boulanger, CEO of LeddarTech. “This relationship is driven by our commitment to pushing the boundaries of automotive technology by delivering cutting-edge solutions that enhance safety, efficiency and driver experiences. Our team is very excited to continue working with Ficosa on the next phase of the collaboration,” Mr. Boulanger concluded.

“At Ficosa, we strive to contribute to building a safer, more comfortable and efficient mobility of the future for everyone,” stated Josep Maria Forcadell, Chief Technology Officer at Ficosa. “In this sense, this innovative, intelligent automatic parking assistant that combines the fusion of LeddarTech’s low-level sensor and perception capabilities and Ficosa’s surround-view camera system will have a significantly positive impact, providing even more detailed and accurate perception of the environment,” Mr. Forcadell concluded.

About Ficosa

Ficosa is a leading global company dedicated to the research, development, production and marketing of advanced vision, safety and efficiency solutions for the automotive industry, with a vocation to contribute to society through its commitment to technological innovation, human values and energy efficiency. Founded in 1949 and with headquarters in Barcelona, Ficosa currently employs more than 8,500 people and has production and R&D centers and sales offices in Europe, North and South America, Asia and Africa. The Rear-View System (interior/side mirror) is Ficosa’s main, globally renowned business, which is recognized by the world’s leading original equipment manufacturers (OEMs). www.ficosa.com

Social media: Twitter @FICOSA_Int; LinkedIn Ficosa

For more information: Ficosa Communication Department
Mònica Acero: macero@llorenteycuenca.com +34 615 07 59 81
Pau Guerrero: pguerrero@llorenteycuenca.com

About LeddarTech

A global software company founded in 2007 and headquartered in Quebec City with additional R&D centers in Montreal, Toronto and Tel Aviv, Israel, LeddarTech develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. LeddarTech’s automotive-grade software applies advanced AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for better decision making and safer navigation. This high-performance, scalable, cost-effective technology is available to OEMs and Tier 1-2 suppliers to efficiently implement automotive and off-road vehicle ADAS solutions.

LeddarTech is responsible for several remote-sensing innovations, with over 150 patents granted or applied for that enhance ADAS and AD capabilities. Better awareness around the vehicle is critical in making global mobility safer, more efficient, sustainable and affordable: this is what drives LeddarTech to seek to become the most widely adopted sensor fusion and perception software solution.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc. Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

• Investor relations website: https://investors.leddartech.com
• Investor relations contact: Kevin Hunt, ICR Inc. kevin.hunt@IcrInc.com
• Financial media contact: Dan Brennan, ICR Inc. dan.brennan@icrinc.com

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

GlobeNewswire Distribution ID 8871621

QUÉBEC, 12 juill. 2023 (GLOBE NEWSWIRE) — LeddarTech^®, une société de logiciels automobiles qui fournit des technologies logicielles de fusion bas niveau de capteurs et de perception innovatrices et brevetées pour systèmes avancés d’aide à la conduite (systèmes ADAS) et de conduite autonome (systèmes AD), est heureuse d’annoncer l’intégration réussie de son logiciel avancé LeddarVision avec le système de vision périphérique de pointe de Ficosa, ainsi qu’avec d’autres capteurs comme des radars, une IMU et un GPS. Ficosa est une entreprise mondiale de premier plan dédiée à la recherche, au développement, à la production et à la commercialisation de solutions de vision, de sécurité et d’efficacité avancées pour l’industrie automobile.

Cette étape importante marque un grand pas en avant dans la collaboration stratégique annoncée en décembre 2022 par Ficosa portant sur l’intégration du logiciel LeddarVision dans les systèmes ADAS de Ficosa pour le stationnement. LeddarVision est un logiciel de fusion de capteurs et de perception performant qui génère des modèles 3D extrêmement précis de l’environnement du véhicule, élaborés à partir des données brutes en provenance des capteurs. L’intégration de ce logiciel avec la technologie de vision réputée de Ficosa met en évidence le plein potentiel d’utilisation de l’assistant de stationnement intelligent de Ficosa dans les systèmes ADAS et AD.

Dans le cadre de leur vision commune de la consolidation du véhicule autonome, LeddarTech et Ficosa continuent de renforcer leur collaboration stratégique en vue de développer un assistant de stationnement intelligent avant-gardiste, permettant une perception de l’environnement encore plus détaillée. Les équipes d’architecture matérielle et logicielle commenceront à équiper une voiture en Israël qui sera utilisée, en collaboration, pour développer et démontrer les fonctionnalités de perception touchant la conduite et l’aide au stationnement intelligentes. Ensuite, deux autres véhicules seront ajoutés à la flotte en Europe afin de présenter la mise en œuvre logicielle et matérielle complète entourant l’aide au stationnement intelligente.

« LeddarTech est très heureuse de participer à cette collaboration et de célébrer le succès de l’intégration de son logiciel LeddarVision et de la technologie de vision de Ficosa », a fait remarquer Charles Boulanger, chef de la direction de LeddarTech. « Cette relation est motivée par notre engagement à repousser les limites de la technologie automobile en fournissant des solutions de pointe qui améliorent la sécurité, l’efficacité et l’expérience conducteur. Notre équipe est enthousiaste à l’idée de continuer à travailler avec Ficosa sur la prochaine phase de la collaboration », a conclu M. Boulanger.

« Chez Ficosa, nous nous efforçons de contribuer à la construction d’une mobilité future plus sûre, plus confortable et plus efficace pour tout le monde », a indiqué pour sa part Josep Maria Forcadell, chef de la technologie chez Ficosa. « Dans ce sens, cet assistant de stationnement automatique intelligent innovateur, qui combine les fonctionnalités de fusion de bas niveau et de perception de LeddarTech et le système de vision périphérique de Ficosa, aura un impact positif important en permettant une perception encore plus précise et détaillée de l’environnement », a conclu M. Forcadell.

À propos de Ficosa

Ficosa est une entreprise mondiale de premier plan dédiée à la recherche, au développement, à la production et à la commercialisation de solutions de vision, de sécurité et d’efficacité avancées pour l’industrie automobile, et qui a pour vocation de contribuer à la société par son engagement dans l’innovation technologique, les valeurs humaines et l’efficacité énergétique. Fondée en 1949 et basée à Barcelone, Ficosa emploie actuellement plus de 8 500 personnes et dispose de centres de production et de R&D ainsi que de bureaux de vente en Europe, en Amérique du Nord et du Sud, en Asie et en Afrique. Le système de surveillance de recul intelligent IRMS de Ficosa, le produit phare de l’entreprise, est reconnu par les principaux équipementiers automobiles du monde entier.   www.ficosa.com

Médias sociaux : Twitter @FICOSA_Int; LinkedIn Ficosa

Pour renseignements : service des communications de Ficosa
Mònica Acero : macero@llorenteycuenca.com +34 615 07 59 81
Pau Guerrero : pguerrero@llorenteycuenca.com

À propos de LeddarTech

Entreprise mondiale de logiciels fondée en 2007, basée à Québec et disposant de centres de R&D supplémentaires à Montréal, Toronto et Tel Aviv (Israël), LeddarTech développe et propose des solutions de perception logicielles complètes qui permettent le déploiement d’applications ADAS et de conduite autonome (AD). Le logiciel de classe automobile de LeddarTech applique l’intelligence artificielle avancée et des algorithmes de vision numérique afin de générer des modèles 3D précis de l’environnement, pour une meilleure prise de décision et une navigation plus sûre. Cette technologie performante, évolutive et économique permet la mise en œuvre efficace de solutions ADAS pour véhicules automobiles et hors route par les équipementiers et fournisseurs de rang 1 et 2.

Détentrice de plus de 150 brevets accordés ou déposés qui améliorent les capacités des systèmes d’aide à la conduite et de conduite autonome, l’entreprise a contribué à plusieurs innovations liées à des applications de télédétection. Une plus grande conscience situationnelle est essentielle pour rendre la mobilité plus sûre, efficace, durable et abordable : c’est ce qui motive LeddarTech à vouloir devenir la solution logicielle de fusion des données de capteurs et de perception la plus largement adoptée.

Renseignements complémentaires disponibles sur www.leddartech.com et sur LinkedIn, Twitter, Facebook et YouTube.

Contact :
Daniel Aitken, vice-président, Marketing, communications et relations avec les investisseurs mondiaux, LeddarTech Inc.
Tél. : + 1-418-653-9000 poste 232 daniel.aitken@leddartech.com

• Site web, relations investisseurs : https://investors.leddartech.com
• Contact, relations investisseurs : Kevin Hunt, ICR Inc. kevin.hunt@IcrInc.com
• Contact, médias financiers : Dan Brennan, ICR Inc. dan.brennan@icrinc.com

Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision et les logos associés sont des marques de commerce ou des marques déposées de LeddarTech Inc. et de ses filiales. Tous les autres noms de marques, noms de produits et marques sont ou peuvent être des marques de commerce ou des marques déposées utilisées pour désigner les produits ou les services de leurs propriétaires respectifs.

GlobeNewswire Distribution ID 8871621